News
Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...
Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...
The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...
Texas reports no new measles cases for the first time since February, maintaining 742 total cases. Meanwhile, Novo Nordisk's Ozempic is linked to rare serious eye disorders, possibly causing vision ...
Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...
Led by researchers at NYU Grossman School of Medicine, the study reveals key details about how cells process fuels like ...
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has experienced a 60% sales increase in India between April and May.
WEIGHT loss jabs could prevent a medication taken by millions of women from working – and increase patients’ risk of cancer. The British Menopause Society said the jabs could cause ...
6h
NDTV Profit on MSNObesity Drugs Pick Pace In India — Can Consumption Sector Withstand A $21 Billion Disruption? | Open InterestIn this edition of Open Interest, we look at how the focus on GLP-1 could reduce household dietary intake and grocery bills.
Since its launch in late March, Mounjaro sales have trebled. Winselow Tucker, president and general manager of Lilly in India ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results